MedTrace Logo

Diffusion-weighted MRI for Individualized Radiation Therapy Planning of Lung Cancer

NCT02059889 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2016-12-16

No results posted yet for this study

Summary

This clinical trial studies diffusion-weighted magnetic resonance imaging (MRI) in identifying and localizing tumors in patients with non-small cell lung cancer undergoing radiation therapy. Diagnostic procedures such as diffusion weighted MRI may help identify where active cancer is to improve the targeting accuracy of radiotherapy. Comparing results of diagnostic procedures done before, during, and after radiation therapy may help determine how the location and volume of tumors changes over time and predict how the tumor will respond to therapy.

Conditions

  • Recurrent Non-small Cell Lung Cancer
  • Stage IIA Non-small Cell Lung Cancer
  • Stage IIB Non-small Cell Lung Cancer
  • Stage IIIA Non-small Cell Lung Cancer
  • Stage IIIB Non-small Cell Lung Cancer

Interventions

DEVICE

diffusion-weighted magnetic resonance imaging

Undergo diffusion-weighted MRI

DEVICE

4-dimensional computed tomography

Undergo 4D CT

RADIATION

fludeoxyglucose F 18

Undergo FDG-PET

DEVICE

FDG-PET

Undergo FDG-PET

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • Elisabeth Weiss, MD · Massey Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02059889 on ClinicalTrials.gov